XM does not provide services to residents of the United States of America.
C
C

CSX

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Canada railways warn of Aug. 22 lockout without labor deal

UPDATE 4-Canada railways warn of Aug. 22 lockout without labor deal Adds request by CN for federal intervention, comments from union paragraphs 1, 4-5, 8 OTTAWA, Aug 9 (Reuters) - C anada's two main rail companies said on Friday they would lock out employees on Aug. 22 if talks to negotiate a labor contract fail , a move that would bring the country's transport of goods to a halt .
C

U.S. STOCKS Lumen Technologies, Broadridge Financial, IDEXX

BUZZ-U.S. STOCKS ON THE MOVE-Lumen Technologies, Broadridge Financial, IDEXX Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes rose over 1% on Tuesday, as investors looked for bargains after a global stock selloff and dovish comments from Federal Reserve officials lifted market sentiment.
A
A
B
C
I
U
U
F
M
R
T
U
B
J
M

CSX rises after Q2 profit tops expectations

BUZZ-CSX rises after Q2 profit tops expectations ** CSX Corp's CSX.O shares up 2% at $33.67 premarket after U.S. railroad operator's qtrly earnings surpass expectations ** Q2 adj EPS of 49 cents beat consensus by a penny, per LSEG, as co benefited from higher shipment volumes, robust pricing ** Rev of $3.7 bln in qtr inline with Street ** JP Morgan, which rates CSX "overweight", boosted its PT by $3 to $42 ** CSX will outperform rail peers after Q2 results were "significantly better than expecte
C
U

U.S. Actinium, Albemarle, ArcBest

U.S. RESEARCH ROUNDUP- Actinium, Albemarle, ArcBest Aug 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Actinium Pharmaceuticals, Albemarle and ArcBest, on Tuesday. HIGHLIGHTS * Actinium Pharmaceuticals Inc ATNM.A : JonesTrading cuts PT to $9 from $26 * Albemarle ALB.N : Baird cuts to neutral; cuts target price to $85 from $102 * ArcBest Corp ARCB.O : Stephens cuts target price to $130 from $145 * Crispr Therapeuti
A
A
B
B
C
C
C
C
D

CSX beats second-quarter profit on better volumes, strong pricing

CSX beats second-quarter profit on better volumes, strong pricing Aug 5 (Reuters) - U.S. railroad operator CSX CSX.O narrowly beat second-quarter profit estimates on Monday, helped by higher shipment volumes and robust pricing, sending its shares up 5% after the bell. Improving intermodal volumes, or goods moved via two or more modes of transport, have helped railroads squeeze out profits along with higher-than-inflation pricing, even as the overall freight industry continues to face a downturn.
C

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.